Overall Status

Completed (20)

Terminated (5)

Recruiting (2)

Unknown status (1)

Withdrawn (1)

Phase

phase 2 (10)

phase 1 (8)

phase 1/phase 2 (4)

n/a (3)

early phase 1 (1)

Collaborator

National Cancer Institute (NCI) (8)

AVEO Pharmaceuticals, Inc. (1)

Fondation ARC (1)

Merck Sharp & Dohme LLC (1)

National Heart, Lung, and Blood Institute (NHLBI) (1)

Novartis (1)

Prometheus Laboratories (1)

Rutgers Cancer Institute of New Jersey (1)

University of Angers, GRANEM (1)

Study Documents

Intervention Type

drug (22)

other (18)

biological (13)

procedure (9)

radiation (2)

genetic (1)

Funder Type

NIH (15)

Other (14)

Study Type

Interventional (26)

Observational (3)

Stage III Renal Cell Cancer

Showing 26 - 29 of 29

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer Trial in San Antonio (drug,

Completed

Clear Cell Renal Cell Carcinoma
+3 more

sorafenib tosylate
+2 more

San Antonio, Texas

Southwest Oncology Group

Feb 27, 2013

Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases Trial in Columbus (recombinant interleukin-12,

Completed

Advanced Adult Primary Liver Cancer
+126 more

recombinant interleukin-12
ABI-007/carboplatin/trastuzumab

Columbus, Ohio

Ohio State University Medical Center

Feb 27, 2013

Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in San Antonio (erlotinib HCl,

Completed

Recurrent Renal Cell Cancer
+2 more

erlotinib hydrochloride
laboratory biomarker analysis

San Antonio, Texas

Southwest Oncology Group

Feb 27, 2013

Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Chicago (biological, drug, other)

Completed

Recurrent Renal Cell Cancer
+2 more

aldesleukin
+2 more

Chicago, Illinois

University of Chicago Comprehensive Cancer Center

Jan 23, 2013